Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T12:53:02.712Z Has data issue: false hasContentIssue false
  • English
  • Français

The metabolic syndrom and the prescription of psychotropic drugs in children and adolescents: three clinical cases

Published online by Cambridge University Press:  19 July 2023

Z. Elmaataoui ,
H. Belhadga  and
H. Kisra
Z. Elmaataoui*
Affiliation:
Hospital Ar-Razi of Sale, Sale, Morocco
H. Belhadga
Affiliation:
Hospital Ar-Razi of Sale, Sale, Morocco
H. Kisra
Affiliation:
Hospital Ar-Razi of Sale, Sale, Morocco
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antipsychotics have shown their interest in several pathologies of the child and the adolescent. However, in this vulnerable population, they are not without adverse effects. Depending on the type of molecule used, classical neuroleptics or second generation antipsychotics, but also within these own classes, the profile of tolerance and adverse effects differs. In this sense, children treated with psychotropic drugs have a higher risk of developing metabolic syndrome compared to children who do not take this treatment.

Objectives

The aim of this work is to discuss the metabolic syndrome in children treated with psychotropic drugs and this through three clinical vignettes.

Methods

we conducted our study through an analysis of three clinical cases

Results

It is about three children followed in the service of child psychiatry of the hospital Ar-razi of salé, aged respectively 11, 13 and 14 years, these children were put under psychotropic drugs for various mental disorders and developed during the evolution of metabolic side effects in particular a dyslipidemia, a diabetes of type 2 revealed by a diabetic ketoacidosis and a hyperprolactinemia.

Conclusions

Systematic monitoring and preventive programs targeting weight gain and metabolic side effects should be an integral part of the overall management of adolescents on psychotropic medications.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S749
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.